噬菌体疗法市场规模、份额和成长分析（按产品、类型、疾病适应症、最终用户和地区划分）—产业预测（2026-2033 年）

预计到 2024 年，全球噬菌体疗法市场规模将达到 3,499 万美元，到 2025 年将成长至 4,107 万美元，到 2033 年将成长至 1.4822 亿美元，在预测期（2026-2033 年）内复合年增长率为 17.4%。

全球噬菌体疗法市场正在扩张，其主要驱动力是应对抗生素抗药性的迫切需求，抗生素抗药性对公共卫生构成重大威胁。推动市场成长的关键因素包括多重抗药性细菌感染疾病的普遍存在、对替代抗菌策略投资的增加以及各领域研发投入的活性化。噬菌体疗法因其对有害细菌的特异性、对微生物群的保护以及副作用极小而成为一种极具吸引力的替代方案。然而，监管的不确定性、临床证据的缺乏以及构建个性化噬菌体混合物的复杂性等挑战依然存在，阻碍了其主流应用。儘管如此，基因组技术的进步以及生物技术公司与学术机构之间合作的加强表明，噬菌体疗法在对抗超级细菌和创新抗感染疗法方面拥有广阔的应用前景。

全球噬菌体疗法市场驱动因素

全球噬菌体疗法市场的成长主要受抗菌素抗药性（AMR）问题日益严重的推动。随着细菌不断进化并对传统抗生素产生抗药性，感染疾病的治疗难度也随之增加。滥用和过度使用这些药物会加剧抗菌素抗药性，导致死亡率上升、疾病传播广泛以及医疗成本飙升。应对这场公共卫生危机的迫切性日益凸显，使得噬菌体疗法等替代疗法备受关注。此外，慢性感染疾病的不断增加也进一步推动了对能够有效对抗抗药性菌株的创新治疗方法的需求。

限制全球噬菌体疗法市场的因素

全球噬菌体疗法市场面临的一大障碍是缺乏支持其疗效和安全性的临床证据。在该领域进行的许多研究规模有限，通常仅涉及小规模受试者或依赖同情用药，未能达到大规模随机对照试验的严格标准。这种缺乏可靠证据的情况削弱了医疗专业人员和监管机构对噬菌体疗法的信心。因此，获得核准、提高医疗服务提供者的接受度以及实现扩充性都面临许多困难，阻碍了噬菌体疗法的有效商业化和整合到现有治疗通讯协定中。

全球噬菌体疗法市场趋势

全球噬菌体疗法市场正呈现出显着的趋势，即整合人工智慧和生物资讯等先进技术，以提高治疗的特异性和疗效。研发人员正投资于人工智慧驱动的噬菌体宿主预测程序和自动化噬菌体筛检平台，这些平台能够简化开发流程，同时降低相关成本和前置作业时间。这项技术进步不仅能够提供更快、更精准的治疗方案，也符合个人化医疗的发展趋势。因此，在这些创新技术的推动下，噬菌体疗法的广泛应用有望重塑医疗保健领域应对感染疾病控制和抗生素抗药性的方式。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术进步
• 案例研究
• 专利分析

全球噬菌体疗法市场规模（按产品和复合年增长率划分）（2026-2033 年）

• 大肠桿菌
• 金黄色葡萄球菌
• 沙门氏菌
• 铜绿假单胞菌
• 其他的

全球噬菌体疗法市场规模（按类型和复合年增长率划分）（2026-2033 年）

• 双链DNA噬菌体
• 单股DNA噬菌体
• 单股RNA噬菌体
• 其他的

全球噬菌体疗法市场规模（按疾病适应症和复合年增长率划分）（2026-2033 年）

• 尿道感染
• 慢性中耳炎
• 慢性溃疡性大肠炎
• 骨感染疾病
• 伤口和皮肤感染疾病
• 囊肿纤维化
• 其他疾病适应症

全球噬菌体疗法市场规模（按最终用户划分）及复合年增长率（2026-2033 年）

• 医院和诊所
• 研究和学术机构
• 其他的

全球噬菌体疗法市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Armata Pharmaceuticals（United States）
• BiomX Inc.（Israel）
• Intralytix（United States）
• Locus Biosciences（United States）
• Amplify Biosciences（United States）
• EnBiotix（United States）
• PhagoMed Biopharma（Austria）
• Transgene SA（France）
• Imugene Ltd（Australia）
• Evotec SE（Germany）
• Novolytics（United Kingdom）
• GangaGen Biotechnologies（India）
• Pherecydes Pharma（France）
• Eligo Bioscience（France）
• Micreos（Netherlands）
• ContraFect Corporation（United States）
• Phagomed Biopharma GmbH（Austria）
• PhagePro Inc.（United States）
• TechnoPhage（Portugal）
• Intralytix, Inc.（United States）

结论与建议

Global Phage Therapy Market size was valued at USD 34.99 Million in 2024 and is poised to grow from USD 41.07 Million in 2025 to USD 148.22 Million by 2033, growing at a CAGR of 17.4% during the forecast period (2026-2033).

The global Phage Therapy Market is on the rise, driven by the urgent need to address antibiotic resistance, which poses a significant threat to public health. Key factors fueling market growth include the prevalence of multidrug-resistant bacterial infections, increased investment in alternative antimicrobial strategies, and heightened research and development efforts from various sectors. Phage therapy's specificity for harmful bacteria, preservation of the microbiome, and lack of side effects make it an attractive alternative. However, challenges remain, including regulatory uncertainties, limited clinical evidence, and the complexity of creating tailored phage cocktails, which hinder mainstream adoption. Nevertheless, advancements in genomic technologies and increasing collaborations between biotech firms and academia suggest a promising future for phage therapy in combating superbugs and revolutionizing anti-infective treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Phage Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Phage Therapy Market Segments Analysis

Global Phage Therapy Market is segmented by Product, Type, Disease Indication, End User and region. Based on Product, the market is segmented into Escherichia coli, Staphylococcus aureus, Salmonella, Pseudomonas aeruginosa and Others. Based on Type, the market is segmented into DsDNA Bacteriophage, SsDNA Bacteriophage, SsRNA Bacteriophage and Others. Based on Disease Indication, the market is segmented into Urinary Tract Infections, Chronic Otitis, Chronic Ulcerative Colitis, Bone Infection, Wound and Skin Infections, Cystic Fibrosis and Other Disease Indications. Based on End User, the market is segmented into Hospital & Clinics, Research & Academic Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Phage Therapy Market

The Global Phage Therapy market is driven by the growing challenge of antimicrobial resistance (AMR), as bacteria evolve and become resistant to conventional antibiotics, rendering infections increasingly difficult to treat. The misuse and overuse of these medications have led to heightened levels of AMR, resulting in greater mortality rates, the spread of diseases, and escalating healthcare costs. As the urgency to address this public health crisis intensifies, alternative treatment modalities such as phage therapy are gaining traction. Additionally, the rising prevalence of chronic infections further fuels the demand for innovative therapeutic options that can effectively combat resistant bacterial strains.

Restraints in the Global Phage Therapy Market

A prominent obstacle in the global phage therapy market is the insufficient clinical evidence supporting its efficacy and safety. Many studies conducted in this field are limited in scope, often involving small participant groups or relying on compassionate use, which do not meet the rigorous standards set by large randomized controlled trials. This lack of robust evidence diminishes the confidence of medical professionals and regulators in phage treatments. Consequently, securing approval, fostering acceptance among healthcare providers, and achieving scalability becomes challenging, hindering the effective commercialization and integration of phage therapy into established treatment protocols.

Market Trends of the Global Phage Therapy Market

The Global Phage Therapy market is witnessing a significant trend towards the integration of advanced technologies such as artificial intelligence and bioinformatics, aimed at enhancing treatment specificity and efficacy. Developers are investing in AI-assisted phage-host prediction programs and automated phage screening platforms, which streamline the development process while reducing associated costs and lead times. This technological advancement not only facilitates quicker and more precise therapeutic options but also aligns with the growing shift towards personalized medicine. Consequently, the increasing adoption of phage therapy reinforced by these innovations is expected to reshape infection management and antibiotic resistance strategies in healthcare.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Case Studies
• Patent Analysis

Global Phage Therapy Market Size by Product & CAGR (2026-2033)

• Market Overview
• Escherichia coli
• Staphylococcus aureus
• Salmonella
• Pseudomonas aeruginosa
• Others

Global Phage Therapy Market Size by Type & CAGR (2026-2033)

• Market Overview
• DsDNA Bacteriophage
• SsDNA Bacteriophage
• SsRNA Bacteriophage
• Others

Global Phage Therapy Market Size by Disease Indication & CAGR (2026-2033)

• Market Overview
• Urinary Tract Infections
• Chronic Otitis
• Chronic Ulcerative Colitis
• Bone Infection
• Wound and Skin Infections
• Cystic Fibrosis
• Other Disease Indications

Global Phage Therapy Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospital & Clinics
• Research & Academic Institutes
• Others

Global Phage Therapy Market Size & CAGR (2026-2033)

• North America (Product, Type, Disease Indication, End User)
  • US
  • Canada
• Europe (Product, Type, Disease Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Type, Disease Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Type, Disease Indication, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Type, Disease Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Armata Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BiomX Inc. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intralytix (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Locus Biosciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amplify Biosciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EnBiotix (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PhagoMed Biopharma (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Transgene S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Imugene Ltd (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evotec SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novolytics (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GangaGen Biotechnologies (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pherecydes Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eligo Bioscience (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Micreos (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ContraFect Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phagomed Biopharma GmbH (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PhagePro Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TechnoPhage (Portugal)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intralytix, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations